|
Mr. Wiberg brings to Catalyst 20 years of business development, finance and Wall Street experience. Mr. Wiberg joins Catalyst from ALZA Corporation, where he was most recently Vice President, Business Development from 2001 to 2007 with responsibility for product licensing, technology licensing and alliance management. From 1998 to 2001, he had responsibility for mergers & acquisitions and participated in corporate planning & analysis, financings and investor relations. During his time at ALZA, Mr. Wiberg completed a wide variety of transactions, including the $12.8 billion sale of ALZA to Johnson & Johnson, the $700 million acquisition of SEQUUS Pharmaceuticals, in-licenses and out-licenses of products, technology and patents, research collaborations, and spinouts and divestitures. Prior to joining ALZA, Mr. Wiberg was an equity research analyst from 1990 to 1998 at UBS Securities, Hambrecht & Quist and Smith Barney, covering a broad range of growth companies in healthcare services, biotechnology and medical devices. From 1985 to 1990, Mr. Wiberg was an investment banker at Smith Barney. Mr. Wiberg received a B.S. in Finance and Accounting and a B.A.S. in Computer Science Engineering from the University of Pennsylvania. | 